News | August 19, 2022
WuXi STA breaks ground for second manufacturing facility in US
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Company is investing more than €100 million in the expansion of the Halle site
It is a two dose vaccine to be administered intramuscularly at 28 days apart
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
Company hires life science veteran Jessica Cao to join management team
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Subscribe To Our Newsletter & Stay Updated
